Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
What it found
No result yet.
What was tested
Treatment tested
- Azathioprine
Amidophosphoribosyltransferase inhibitor|DNA inhibitor
What it measured
Main measures
The brain structural change over time between the baseline MRI and the follow-up MRIs
On admission to the hospital on day 1, on discharge 180 days later and on follow up 360 days later
MRI lesionsBrain volume lossThe spinal cord change over time between the baseline MRI and the follow-up MRIs.
On admission to the hospital on day 1, on discharge 180 days later and on follow up 360 days later
MRI lesionsThe functional change over time between the baseline MRI and the follow-up MRIs.
On admission to the hospital on day 1, on discharge 180 days later and on follow up 360 days later
MRI lesions
Other measures (3)
Change from Baseline Expanded Disability Status Scale （EDSS）/ Functional Systems （FS）
On admission to the hospital on day 1, on discharge 180 days later and on follow up 360 days later
Disability progressionTimed 25-foot Walk
On admission to the hospital on day 1, on discharge 180 days later and on follow up 360 days later
Disability progressionWalking and mobilityMean change in visual acuity as assessed by Sloan 2.5% low contrast visual acuity chart.
On admission to the hospital on day 1, on discharge 180 days later and on follow up 360 days later
Vision
Who could take part
MS (type not specified) · 16 to 75
Inclusion Criteria: * 16-75 * Diagnosis of neuroinflammatory and demyelination disease * Availability of demographic and clinical data at the time disease onset * Informed written consent obtained from the patient, and/or patient's parent(s), and/or legal representative. Assent, if old enough to grant, will be obtained from all patients under the age of 16 years. Exclusion Criteria: * Patients for whom MRI is contra-indicated * Patients included in an ongoing clinical trial where the product is blinded
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
CLUE is a prospective study to assess structural and functional changes of the brain, spinal cord, and optic nerve, as well as the inflammatory environment in patients with neuroinflammatory and demyelinating diseases. Participants will receive magnetic resonance (MR) techniques including DIR, DKI, QSM, Rs-fMRI, conventional sequences (T1WI/T2WI/FLAIR), and the MR metabolic SPICE sequence, and will be followed up for one year using 3T MRI. In addition, participants will receive a one-time baseline examination including T1WI, T2WI, FLAIR, and SWI sequences on 7T MRI, as well as PET-MRI.
Papers
Results
Persistently Gadolinium-Enhancing Lesion Is a Predictor of Poor Prognosis in NMOSD Attack: a Clinical Trial.Neurotherapeutics · 2021
Loading reviews and guidelines…
Related trials
- COVID-19 Booster Vaccine in Autoimmune Disease Non-Respon…
Phase 2 · Stopped early
Stopped early
- AUTOLOUGUS STEM CELLS TRANSPLANTATION IN SM
Phase 1 · —
No result found
- High Dose Chemo With Stem Cell Transplant as Treatment fo…
Phase 2 · Stopped early
Stopped early
- Tolerance induction with intravenous IFNβ-1a
Phase 2 · Stopped early
Stopped early
- MITOX-REBIF
Phase 3 · Completed
No result found
- IQUALYSEP
Not a drug-phase study · Completed
No result found
History
Started
Jan 2019
Main results due
Dec 2027
Finished
Dec 2028
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error